Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) Trial
- 1 February 2005
- journal article
- other
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 12 (1) , 75-81
Abstract
Background: In recent large cardiovascular trials done in stable patients, 14-31% of the participants were smokers; the consequences of smoking in these trials using medications known to reduce cardiovascular events, have not been assessed. Design: We evaluated the cardiovascular outcomes according to smoking status of men and women participating in the Heart Outcomes Prevention Evaluation trial. Methods: The occurrence of cardiovascular events was documented among participants who did not change their smoking status during the trial. There were 2728 ‘never smokers’, 5241 ‘former smokers’ and 936 ‘current smokers’, and all had stable cardiovascular disease or diabetes with at least one other risk factor. None had previous congestive heart failure or known left ventricular ejection fraction < 0.40. Results: During the 4.5-year follow-up, there were 641 cardiovascular deaths, 978 myocardial infarctions, 358 strokes and 1021 deaths. In comparison to ‘never smokers’, smokers had relative risks adjusted for confounding variables including medications known to reduce cardiovascular mortality and morbidity, for cardiovascular death of 1.65 [95% confidence interval (CI), 1.28-2.14], for myocardial infarction of 1.26 (95% CI, 1.01-1.58), for stroke of 1.42 (95% CI, 1.00-2.04), and for total mortality of 1.99 (95% CI, 1.63-2.44). The rates of these events among ‘former smokers’ were not different from those of ‘never smokers’. Conclusions: Smoking increased the risk of mortality and morbidity among high-risk patients despite the use of medications known to reduce cardiovascular events. Smoking cessation programs should be reinforced even for patients participating in clinical trials.Keywords
This publication has 19 references indexed in Scilit:
- The pathophysiology of cigarette smoking and cardiovascular diseaseJACC, 2004
- Estimates of global mortality attributable to smoking in 2000The Lancet, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- The validity of self-reported smoking: a review and meta-analysis.American Journal of Public Health, 1994
- Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project.Stroke, 1994
- Effect of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the coronary artery surgery study (CASS): 10-Year follow-upJACC, 1992
- Cessation of Smoking in Patients with Intermittent ClaudicationActa Medica Scandinavica, 1987
- The Relation of Risk Factors to the Development of Atherosclerosis in Saphenous-Vein Bypass Grafts and the Progression of Disease in the Native CirculationNew England Journal of Medicine, 1984